c-Triadem:一种受约束,可解释的深度学习模型,用于识别阿尔茨海默病中的新生物标志物
Sherlyn Jemimah1, Ferial Abuhantash1, Aamna AlShehhi1,2
1Department of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
medRxiv : the preprint server for health sciences
|November 28, 2024
概括
一个新的深度学习模型c-Triadem准确地识别血液中的阿尔茨海默病 (AD) 生物标志物. 这一进步有助于早期诊断轻度认知障碍 (MCI) 和AD,改善患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于早期检测,但目前的生物标志物不足.
- 基于血液的诊断为早期阿尔茨海默病的识别提供了一个有希望的替代方案.
研究的目的:
- 开发一种新的深度神经网络,c-Triadem,用于识别基于血液的阿尔茨海默病生物标志物.
- 使用多模式数据准确预测轻度认知障碍 (MCI) 和阿尔茨海默病 (AD).
主要方法:
- 利用受约束的三进制输入深度神经网络 (c-Triadem) 整合基因类型,基因表达和临床数据.
- 在阿尔茨海默氏症神经成像疾病倡议 (ADNI) 的数据上训练了模型.
- 采用了夏普利添加式扩展 (SHAP) 来识别关键的预测基因和临床特征.
主要成果:
- 在预测疾病状况方面,它以97%的曲线下面面积 (AUC) 和89%的准确性实现了卓越的性能.
- 确定了特定的SNP (CASP9,LCK,SDC3) 和基因表达 (PINK1,ATG5,UBB,UBC) 作为具有高度影响力的预测因素.
- 突出了潜在的基于血液的基因标记,与DNA损伤反应和线粒有关.
结论:
- c-Triadem模型在从血液数据中预测MCI和AD方面表现出很高的准确性.
- 促进了对阿尔茨海默病的新型血液基因标记物的发现.
- 该模型显示了在诊断其他相关痴呆症疾病中应用的潜力.
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


